Literature DB >> 33432316

Single chain variable fragment fused to maltose binding protein: a modular nanocarrier platform for the targeted delivery of antitumorals.

Francisco J Reche-Perez1, Simona Plesselova1, Eduardo De Los Reyes-Berbel2, Mariano Ortega-Muñoz1, Francisco J Lopez-Jaramillo2, Fernando Hernandez-Mateo2, Francisco Santoyo-Gonzalez2, Rafael Salto-Gonzalez1, Maria D Giron-Gonzalez1.   

Abstract

The use of the specific binding properties of monoclonal antibody fragments such as single-chain variable fragments (ScFv) for the selective delivery of antitumor therapeutics for cancer cells is attractive due to their smaller size, low immunogenicity, and low-cost production. Although covalent strategies for the preparation of such ScFv-based therapeutic conjugates are prevalent, this approach is not straightforward, as it requires prior chemical activation and/or modification of both the ScFv and the therapeutics for the application of robust chemistries. A non-covalent alternative based on ScFv fused to maltose-binding protein (MBP) acting as a binding adapter is proposed for active targeted delivery. MBP-ScFv proves to be a valuable modular platform to synergistically bind maltose-derivatized therapeutic cargos through the MBP, while preserving the targeting competences provided by the ScFv. The methodology has been tested by using a mutated maltose-binding protein (MBP I334W) with an enhanced affinity toward maltose and an ScFv coding sequence toward the human epidermal growth factor receptor 2 (HER2). Non-covalent binding complexes of the resulting MBP-ScFv fusion protein with diverse maltosylated therapeutic cargos (a near-infrared dye, a maltosylated supramolecular β-cyclodextrin container for doxorubicin, and non-viral polyplex gene vector) were easily prepared and characterized. In vitro and in vivo assays using cell lines that express or not the HER2 epitope, and mice xenografts of HER2 expressing cells demonstrated the capability and versatility of MBP-ScFv for diagnosis, imaging, and drug and plasmid active targeted tumor delivery. Remarkably, the modularity of the MBP-ScFv platform allows the flexible interchange of both the cargos and the coding sequence for the ScFv, allowing ad hoc solutions in targeting delivery without any further optimization since the MBP acts as a pivotal element.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33432316     DOI: 10.1039/d0bm01903h

Source DB:  PubMed          Journal:  Biomater Sci        ISSN: 2047-4830            Impact factor:   6.843


  3 in total

1.  Near-Infrared Fluorescence Imaging of EGFR-Overexpressing Tumors in the Mouse Xenograft Model Using scFv-IRDye800CW and Cetuximab-IRDye800CW.

Authors:  Abolfazl Amini; Yaghoub Safdari; Fatemeh Tash Shamsabadi
Journal:  Mol Imaging       Date:  2022-04-14       Impact factor: 3.250

2.  Expression, purification and characterisation of a human anti-CDK4 single-chain variable fragment antibody.

Authors:  Jialiang Zhao; Jingjing Xu; Tianbin Yang; Xinze Yu; Cheng Cheng; Tong Zhang; Ze Ren; Na Li; Fang Yang; Guiying Li
Journal:  BMC Biotechnol       Date:  2021-12-20       Impact factor: 2.563

3.  Targeted Codelivery of Prodigiosin and Simvastatin Using Smart BioMOF: Functionalization by Recombinant Anti-VEGFR1 scFv.

Authors:  Somayyeh Mirzaeinia; Sedighe Zeinali; Nediljko Budisa; Hamid Reza Karbalaei-Heidari
Journal:  Front Bioeng Biotechnol       Date:  2022-03-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.